Fairpointe Capital’s Gilead Sciences GILD Stock Holding History

Fairpointe Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$751K	Sell	11,619 -2,600	-18%	-$168K	1.13%	29
2020 Q4	$828K	Buy	14,219 +2,453	+21%	+$148K	0.15%	56
2020 Q3	$743K	Sell	11,766 -785	-6%	-$54.4K	0.12%	54
2020 Q2	$966K	Sell	12,551 -5,665	-31%	-$434K	0.14%	53
2020 Q1	$1.36M	Buy	18,216 +3,216	+21%	+$222K	0.2%	51
2019 Q4	$975K	Hold	15,000	–	–	0.07%	54
2019 Q3	$951K	Hold	15,000	–	–	0.05%	56
2019 Q2	$1.01M	Hold	15,000	–	–	0.04%	55
2019 Q1	$975K	Hold	15,000	–	–	0.03%	56
2018 Q4	$938K	Buy	15,000 +5,000	+50%	+$349K	0.03%	57
2018 Q3	$772K	Hold	10,000	–	–	0.02%	61
2018 Q2	$708K	Buy	+10,000	New	+$706K	0.02%	62

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fairpointe Capital's GILD Position: Q1 2021 in Review

Fairpointe Capital reduced its Gilead Sciences (GILD) stake by 18% in Q1 2021, selling an estimated $168K and leaving 11,619 shares worth $751K. The position accounts for 1.13% of the portfolio, ranked #29.

Fairpointe Capital first reported a position in GILD in Q2 2018 and has held it in 12 quarters since. The position peaked at $1.36M in Q1 2020. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

Fairpointe Capital held 11,619 shares of Gilead Sciences worth $751K as of Q1 2021.
Fairpointe Capital sold 2,600 Gilead Sciences shares in Q1 2021, an estimated $168K.
Gilead Sciences made up 1.13% of Fairpointe Capital's portfolio in Q1 2021, its #29 holding.
Fairpointe Capital first reported a position in Gilead Sciences in Q2 2018 and has held it in 12 quarters since.
Fairpointe Capital's Gilead Sciences position peaked at $1.36M in Q1 2020.
1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.